Glycogen storage disease type III natural history, complications and prognosis: Difference between revisions
Line 22: | Line 22: | ||
===Complications=== | ===Complications=== | ||
*Common complications of glycogen storage disease type III include:<ref name="pmid8750616">{{cite journal| author=Lee P, Burch M, Leonard JV| title=Plasma creatine kinase and cardiomyopathy in glycogen storage disease type III. | journal=J Inherit Metab Dis | year= 1995 | volume= 18 | issue= 6 | pages= 751-2 | pmid=8750616 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8750616 }} </ref><ref name="pmid1876514">{{cite journal| author=Labrune P, Huguet P, Odievre M| title=Cardiomyopathy in glycogen-storage disease type III: clinical and echographic study of 18 patients. | journal=Pediatr Cardiol | year= 1991 | volume= 12 | issue= 3 | pages= 161-3 | pmid=1876514 | doi=10.1007/BF02238523 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1876514 }} </ref><ref name="pmid1580445">{{cite journal| author=Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT| title=Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. | journal=Ann Intern Med | year= 1992 | volume= 116 | issue= 11 | pages= 896-900 | pmid=1580445 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1580445 }} </ref><ref name="pmid8273986">{{cite journal| author=Talente GM, Coleman RA, Alter C, Baker L, Brown BI, Cannon RA et al.| title=Glycogen storage disease in adults. | journal=Ann Intern Med | year= 1994 | volume= 120 | issue= 3 | pages= 218-26 | pmid=8273986 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8273986 }} </ref> | *Common complications of glycogen storage disease type III include:<ref name="pmid8750616">{{cite journal| author=Lee P, Burch M, Leonard JV| title=Plasma creatine kinase and cardiomyopathy in glycogen storage disease type III. | journal=J Inherit Metab Dis | year= 1995 | volume= 18 | issue= 6 | pages= 751-2 | pmid=8750616 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8750616 }} </ref><ref name="pmid1876514">{{cite journal| author=Labrune P, Huguet P, Odievre M| title=Cardiomyopathy in glycogen-storage disease type III: clinical and echographic study of 18 patients. | journal=Pediatr Cardiol | year= 1991 | volume= 12 | issue= 3 | pages= 161-3 | pmid=1876514 | doi=10.1007/BF02238523 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1876514 }} </ref><ref name="pmid1580445">{{cite journal| author=Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT| title=Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. | journal=Ann Intern Med | year= 1992 | volume= 116 | issue= 11 | pages= 896-900 | pmid=1580445 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1580445 }} </ref><ref name="pmid8273986">{{cite journal| author=Talente GM, Coleman RA, Alter C, Baker L, Brown BI, Cannon RA et al.| title=Glycogen storage disease in adults. | journal=Ann Intern Med | year= 1994 | volume= 120 | issue= 3 | pages= 218-26 | pmid=8273986 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8273986 }} </ref><ref name="pmid2122109">{{cite journal| author=Smit GP, Fernandes J, Leonard JV, Matthews EE, Moses SW, Odievre M et al.| title=The long-term outcome of patients with glycogen storage diseases. | journal=J Inherit Metab Dis | year= 1990 | volume= 13 | issue= 4 | pages= 411-8 | pmid=2122109 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2122109 }} </ref> | ||
**Left ventricular hypertrophy | **Left ventricular hypertrophy | ||
**Cardiomyopathy | **Cardiomyopathy | ||
** | **Hyperlipidemia | ||
***Hypercholesterolemia | |||
***Hypertriglyceridemia | |||
===Prognosis=== | ===Prognosis=== |
Revision as of 15:23, 12 December 2017
Glycogen storage disease type III Microchapters |
Differentiating Glycogen storage disease type III from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type III natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type III natural history, complications and prognosis |
FDA on Glycogen storage disease type III natural history, complications and prognosis |
CDC on Glycogen storage disease type III natural history, complications and prognosis |
Glycogen storage disease type III natural history, complications and prognosis in the news |
Blogs on Glycogen storage disease type III natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of glycogen storage disease type III include:[1][2][3][4][5]
- Left ventricular hypertrophy
- Cardiomyopathy
- Hyperlipidemia
- Hypercholesterolemia
- Hypertriglyceridemia
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
- Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Lee P, Burch M, Leonard JV (1995). "Plasma creatine kinase and cardiomyopathy in glycogen storage disease type III". J Inherit Metab Dis. 18 (6): 751–2. PMID 8750616.
- ↑ Labrune P, Huguet P, Odievre M (1991). "Cardiomyopathy in glycogen-storage disease type III: clinical and echographic study of 18 patients". Pediatr Cardiol. 12 (3): 161–3. doi:10.1007/BF02238523. PMID 1876514.
- ↑ Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT (1992). "Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy". Ann Intern Med. 116 (11): 896–900. PMID 1580445.
- ↑ Talente GM, Coleman RA, Alter C, Baker L, Brown BI, Cannon RA; et al. (1994). "Glycogen storage disease in adults". Ann Intern Med. 120 (3): 218–26. PMID 8273986.
- ↑ Smit GP, Fernandes J, Leonard JV, Matthews EE, Moses SW, Odievre M; et al. (1990). "The long-term outcome of patients with glycogen storage diseases". J Inherit Metab Dis. 13 (4): 411–8. PMID 2122109.